- Home
- URGN vs MVST Comparison
URGN vs MVST Comparison
Compare URGN & MVST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- URGN
- MVST
- Stock Information
- Founded
- URGN 2004
- MVST 2006
- Country
- URGN United States
- MVST United States
- Employees
- URGN N/A
- MVST N/A
- Industry
- URGN Biotechnology: Pharmaceutical Preparations
- MVST Industrial Machinery/Components
- Sector
- URGN Health Care
- MVST Miscellaneous
- Exchange
- URGN Nasdaq
- MVST Nasdaq
- Market Cap
- URGN 904.0M
- MVST 848.0M
- IPO Year
- URGN 2017
- MVST N/A
- Fundamental
- Price
- URGN $18.94
- MVST $3.32
- Analyst Decision
- URGN Strong Buy
- MVST Strong Buy
- Analyst Count
- URGN 8
- MVST 1
- Target Price
- URGN $28.50
- MVST $6.00
- AVG Volume (30 Days)
- URGN 1.1M
- MVST 4.7M
- Earning Date
- URGN 11-05-2025
- MVST 11-11-2025
- Dividend Yield
- URGN N/A
- MVST N/A
- EPS Growth
- URGN N/A
- MVST N/A
- EPS
- URGN N/A
- MVST N/A
- Revenue
- URGN $94,238,000.00
- MVST $422,605,000.00
- Revenue This Year
- URGN $35.60
- MVST $25.36
- Revenue Next Year
- URGN $129.54
- MVST $30.46
- P/E Ratio
- URGN N/A
- MVST N/A
- Revenue Growth
- URGN 10.85
- MVST 20.84
- 52 Week Low
- URGN $3.42
- MVST $0.15
- 52 Week High
- URGN $21.71
- MVST $4.72
- Technical
- Relative Strength Index (RSI)
- URGN 49.18
- MVST 64.90
- Support Level
- URGN $18.45
- MVST $2.71
- Resistance Level
- URGN $21.71
- MVST $2.98
- Average True Range (ATR)
- URGN 1.18
- MVST 0.18
- MACD
- URGN -0.17
- MVST 0.07
- Stochastic Oscillator
- URGN 20.90
- MVST 95.76
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.